期刊文献+

卷曲霉素和丁胺卡那霉素在老年耐药结核治疗中的对比观察 被引量:6

Comparative Observation of Capreomycin and Amikacin in the Treatment of Aged-Related Multidrug-Resistant Pulmonary Tuberculosis
下载PDF
导出
摘要 目的观察和评价卷曲霉素和丁胺卡那霉素联合化疗方案在耐多药结核病(MDR-TB)治疗中的疗效和副作用。方法将116例MDR-TB患者均衡分为治疗组58例和对照组58例。化疗方案:治疗组用卷曲霉素联合吡嗪酰胺、乙胺丁醇、左氧氟沙星、对氨基水杨酸钠、丙硫异烟胺,对照组用丁胺卡那霉素,联合用药同治疗组。结果共有97例患者完成化疗疗程,治疗组49例,对照组48例。痰菌阴转率治疗组71.4%;对照组52.1%,治疗组明显高于对照组,两组比较差异显著(P<0.05);病灶吸收总有效率治疗组88.8%,对照组64.6%,治疗组优于对照组,两组比较差异显著(P<0.05);治疗组耳毒性肾毒性轻微,且易纠正,总药物不良反应率治疗组为10.2%,对照组为14.6%,治疗组低于对照组,两组比较差异显著(P<0.05)。结论卷曲霉素治疗MDR-TB疗效优于丁胺卡那霉素,副反应小于丁胺卡那霉素,安全有效,值得临床推广应用。 Objective To observe and evaluate the efficacy and side effects of capreomycin (CPM) and amikacin (AMK) combined with chemotherapy in the treatment of multidrug-resistant pulmonary tuberculosis (MDR- TB). Methods 116 cases patients with MDR-TB were averagely divided into the treatment and control groups. Each group had 58 cases. Chemotherapy regimens: the treatment group were given the combination of CPM, PZA, ethambutol(EMB), levofloxacin (LVFX), sodium aminosalicylate (PAS), and Protionamide(PTH), while the control group were given the combination of AMK, PZA, EMB, LVFX, PAS, and PTH. Results 97 patients had completed the chemotherapy treatment, 49 cases were in the treatment group, and 48 cases were in the control group. Sputum negative conversion rate was 71.4% in the treatment group, while the control group was 52.1%, the treatment group was significantly higher than the control group (P 〈 0.05). The foci absorption total effective rate was 88.8% in the treatment group, while the control group was 64.6%, the treatment group was significantly better than the control group (P〈0.05). The ototoxicity and renal toxicity was slight in the treatment group, and easy to correct. The total adverse drug reactions was 10.2%, while the control group was 14.6%. The treatment group was significantly lower than the control group, the differences between the two groups were significant (P 〈0.05). Conclusion CPM was superior to AMK in the treatment of MDR-TB, and side effects was less than AMK, so it is safe and effective, and worthy of clinical application.
作者 苗雅 聂桂英
出处 《国外医药(抗生素分册)》 CAS 2012年第6期I0005-I0007,共3页 World Notes on Antibiotics
关键词 肺结核 耐多药结核病 耐药率 耳毒性 肾毒性 tuberculosis: MDR-TB resistance rate ototoxicity renal toxicity
  • 相关文献

参考文献1

二级参考文献6

  • 1丁大连,中华耳鼻咽喉科杂志,1995年,30卷,323页
  • 2丁大连,中华耳鼻咽喉科杂志,1991年,26卷,154页
  • 3张敬人,中华耳鼻咽喉科杂志,1991年,26卷,3页
  • 4罗德峰,中华耳鼻咽喉科杂志,1990年,25卷,281页
  • 5丁大连,中华耳鼻咽喉科杂志,1986年,21卷,121页
  • 6郝水,细胞生物学教程,1985年,130页

共引文献19

同被引文献55

  • 1王巍,李洪敏,王安生,吴雪琼,李素梅.69例“复治肺结核”患者的病原菌构成、耐药性的临床分析[J].华西医学,2006,21(2):248-249. 被引量:1
  • 2李国刚,董彬,王峰,徐华.复治肺结核病例分枝杆菌分离株药敏试验分析[J].中国公共卫生,2006,22(12):1529-1529. 被引量:2
  • 3Prasad R, Verma S K, Garg R, et al.Drug susceptibility pattern of Mycobacterium tuberculosis isolates from patients of category- Ⅱ failure of pulmonary tuberculosis under directly observed treatment short-course from north India[J].BiosciTrends, 2012, 6(3): 110-114.
  • 4Bates M, O' Grady J, Mwaba P, et al.Evaluation of the burden of unsuspected pulmonary tuberculosis and co-morbidity with non- communicable diseases in sputum producing adult inpatients[J].PLo S One, 2012, 7(7): e40774.
  • 5World Health Organization. Muhidug and extensively drug-resistant TB (M/XDR-TB) 2010 global report on surveillance and response [R]. Geneva: World Health Organization, 2010: 26-28.
  • 6World Health Organization. Stop TB partnership global MDR- TB&XDR-TB response pl, an 2007-2008 JR]. Geneva: World health Organization, 2007 : 49-52.
  • 7World Health Organization. Guideline for the programmatic management of drug-resistant tubercuiosis emergency update2008 [R]. Geneva: World Health Organization, 2008: 36-37.
  • 8Mirsaeidi SM, Tabarsi P, Khoshnood K, et al. Treatment of multiple Drug-Resisitant tberculosis (MDR-TB) in Iran [J]. Int J Infect Dis, 2005, 9 (6): 317-322.
  • 9李亮,郑素华,初乃惠,谢艳光,杨应周,李群,王晓萌,闫兴录,谭卫国,缪梓萍,端木宏谨.结核病控制项目地区耐药结核病两种治疗方案的对比研究[J].中华医学杂志,2008,88(48):3387-3391. 被引量:4
  • 10唐神结,肖和平,李红,桂徐蔚,顾瑾,粱莉,孙华,闫丽萍.经皮肺穿刺注药治疗耐多药肺结核空洞的近远期疗效观察[J].中国防痨杂志,2009,31(2):94-99. 被引量:19

引证文献6

二级引证文献34

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部